The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, but its position within the broader sector now triggers questions about future yields . Alternative versions are undercutting market share, causing worries that investing in companies closely tied to Viagra's once-dominant influence could be a problematic s